CARBON Newsletter (26 November 2024) - Your Latest...
Carbon
Nov. 26, 2024
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Bayer
Main (gene editing) focus: Next-generation in vivo delivered gene-editing therapies
Company stage: Commercial
Diseases (gene editing): Genetic diseases of the liver, haemophilia, ophthalmology and autoimmune diseases
Genome editing tool: CRISPR-Cas9, Cas14 and Casɸ
Funding stage: Public (XETRA:BAYN.DE)
Location: Berlin, Germany
Website: https://www.bayer.com/en/pharma/development-pipeline
Pipeline: https://www.bayer.com/en/pharmaceuticals
Gene editing partnerships: Mammoth Biosciences, Casebia Therapeutics
Bayer is a big pharma company with worldwide operations. The company is engaged in the gene-editing field by its joint venture firm, Casebia Therapeutics, which it launched together with CRISPR Therapeutics. The company also announced a collaboration with Mammoth Biosciences, where the two companies will utilise Mammoth's ultra-small Cas enzymes, Cas14 and Casɸ, for in vivo gene editing of multiple disease targets.
